Background/Aims: To describe the toxicity profile of anti-neoplastic agents from real clinical settings, we analyzed spontaneously reported adverse events (AEs) using data from the adverse drug reaction (ADR) reporting system of the Korean Food and Drug Administration (KFDA). Methods: Data were extracted from the nationwide spontaneous ADR reporting system of KFDA from July 2009 to December 2010. We extracted and analyzed data related to chemotherapy and identified unlabeled ADR that were not described in the package insert of the products. Results: In total, 5,867 cases of antineoplastic agent-related AE reports were identified after excluding cases for duplication and cases assessed as 'unlikely' and 'unclassifiable', based on expert opinion. Of the patients with AEs, 52.4% were males and the median age was 56 years. In total, 460 AEs (7.8%) from 267 patients were reported as 'serious' AEs. The most common causative anti-cancer drug class was pyrimidine analogs (31.5%), followed by platinum compounds (19.9%), protein kinase inhibitors (10.8%), and taxanes (8.8%). The most common clinical manifestation of AEs was gastrointestinal toxicities (25.5%), followed by skin disorders (25.3%), and generalized reactions (14.3%). In total, 168 cases (2.9%) of unlabeled AEs were identified. Among these, 10 were reported as serious AEs.
.
특정약물에 의한 기관계별 유해사례 보고 건수와 특정약
제에 의한 주요 유해반응이 항상 일치하지는 않았다 (Fig. 1) . (9) Sunitinib (122) Gefitinib (98) Dasatinib (6) Imatinib (116) Nilotinib (9) Everolimus (3) Taxanes (L01CD) 518
Paclitaxel (271) Docetaxel (247) Folic acid analogues 260
Methotrexate (212) Pemetrexed (48) Nitrogen mustard analogs 212
Cyclophosphamide (138) Ifosfamide (66) Melphalan (7) Anthracyclines and related substances 207
Doxorubicin (156) Daunorubicin (9) Mitoxantrone (12) Idarubicin (25) Epirubicin (5) Monoclonal antibodies 190
Rituximab (143) Cetuximab (22) Trastuzumab (17) Bevacizumab (8) Podophyllotoxin derivatives 135
Etoposide (135)
Vinca alkaloids and analogs 106
Vincristine (67) Vinorelbine (35) Vinblastine (4) Interferons (IFNs) 54
IFNα-2b (21) IFNα-2a (18) IFNγ (14) IFNα-n1 (1) Purine analogs 39
Mercaptopurine (19) Fludarabine (18) Cladribine (2) Anti-estrogens & Enzyme inhibitors 69
Tamoxifen (48) Anastrozole (12) Letrozole (8) Exemestane (1) Nitrosoureas 12
Lomustine (6) Carmustine (6) Gonadotropin releasing hormone analogs 7
Goserelin (5) Leuprorelin (2) Others Irinotecan (166) Thalidomide (14) Tretinoin (7) Bicalutamide (3) Asparaginase (75) Aldesleukin (14) Polysaccharide K (7) Altretamine (3) Bleomycin (19) Dacarbazine (8) Medroxyprogesterone (7) Estramustine (2) Bortezomib (16) Helixor Ⓡ (9) Hydroxycarbamide (6) Anagrelide (1) Temozolomide (15) Busulfan (8) Belotecan (5) Dactinomycin (1) Topotecan (14) Procarbazine (8) Mitomycin (4) Lomustine myalgia [1] Medroxyprogesterone paresthesia [1] , dyspepsia [1] , flank pain [1] Melphalan flushing [1] Methotrexate dizziness [7] , paresthesia [2] , electrolyte abnormality* [1] , hyperuricemia [1] , lip pain [1] , upward deviation of eyes a [2] , weight loss [1] Oxaliplatin hyperammonemia a [1] , erectile dysfunction [1] Pemetrexed dizziness [3] , skin hyperpigmentation [1] , chills [1] Polysaccharide K dermatitis herpetiformis a [1] , white blood cell decreased [1] , fever [1] 있었다 [15, 16] . 중심 단어: 항암제; 약물부작용 보고체계; 약물독성; 종양
